EPS Creative Health Technology Group Ltd.
The drug discovery business is led by our subsidiary, EPS Innovative Medicine (Japan) Limited. The drug candidates our company owns and our business outline are as follows.
EIM-001 owned by FEF Pharmaceutical Co., Ltd. is one of the neovascularization drug candidates for treatment of peripheral artery diseases. FEF Pharmaceutical Co., Ltd. aims to establish a new treatment option so that EIM-001 becomes an alternative to highly invasive surgical bypass surgery in peripheral artery diseases.
FEF Pharmaceutical Co., Ltd. : https://fefpharmaceutical.com/ 
| Pipeline | Target Disease | Area | Stage | |||||
| Basic research phase | Non-clinical | Clinical Trial Phase | Approval | |||||
| I | II | III | ||||||
| EIM-001 | Peripheral artery diseases | Japan |  | |||||
Brown fat cell induction technology owned by EPD Co., Ltd. has the potential to be used in regenerative medicine and in the screening of substances that may increase energy consumption. EPD Co., Ltd. is exploring the potential for anti-obesity and anti-diabetes using the brown fat cell induction technology.
EPD Co., Ltd. : https://eps-epd.com/
| Pipeline | Target Disease | Area | Stage | |||||
| Basic research phase | Non-clinical | Clinical Trial Phase | Approval | |||||
| I | II | III | ||||||
| Brown fat cell | Obesity and diabetes | Japan |  | |||||
Research Centre, a research division of EPS Innovative Medicine (Japan) Limited, is pursuing the possibility of sublingual vaccines, focusing on the importance of secretory IgA, which it considers influences defense against allergic diseases as well as against new coronaviruses.
EPS Innovative Medicine (Japan) Co., Ltd. : https://www.eps-inomed.com/
| Pipeline | Target Disease | Area | Stage | |||||
| Basic research phase | Non-clinical | Clinical Trial Phase | Approval | |||||
| I | II | III | ||||||
| Sublingual vaccine | Prevent infectious diseases | Japan | | |||||
